Although most cells located in the tumor context respond to TGF-β in a context-dependent way, extensive evidence suggests that enriched TGF-β expression in the TME may compromise antitumor immunity and limit the efficacy of immunotherapy (80, 112). The gene discussed is TGFB1; the disease is neoplasm.